| Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate AL McCormick, RH Brown Jr, ME Cudkowicz, A Al-Chalabi, JA Garson Neurology 70 (4), 278-283, 2008 | 148 | 2008 |
| Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1 CM Parry, A Kohli, CJ Boinett, GJ Towers, AL McCormick, D Pillay Journal of virology 83 (18), 9094-9101, 2009 | 97 | 2009 |
| Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays RK Gupta, A Kohli, AL McCormick, GJ Towers, D Pillay, CM Parry Aids 24 (11), 1651-1655, 2010 | 96 | 2010 |
| A potent adjuvant effect of CD40 antibody attached to antigen TA Barr, AL Mccormick, J Carlring, AW Heath Immunology 109 (1), 87-92, 2003 | 91 | 2003 |
| Immunization with an interferon-γ–gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120 AL McCormick, MS Thomas, AW Heath The Journal of infectious diseases 184 (11), 1423-1430, 2001 | 77 | 2001 |
| Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine … N Ndembi, RL Goodall, DT Dunn, A McCormick, A Burke, F Lyagoba, ... The Journal of infectious diseases 201 (1), 106-113, 2010 | 67 | 2010 |
| Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis JA Garson, L Usher, A Al-Chalabi, J Huggett, EF Day, AL McCormick Acta neuropathologica communications 7, 1-9, 2019 | 61 | 2019 |
| High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy RK Gupta, RL Goodall, M Ranopa, C Kityo, P Munderi, F Lyagoba, ... Clinical infectious diseases 58 (7), 1023-1026, 2014 | 52 | 2014 |
| An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming S Nimal, AL McCormick, MS Thomas, AW Heath Vaccine 23 (30), 3984-3990, 2005 | 43 | 2005 |
| Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5′ UTR AL McCormick, MJ Macartney, I Abdi-Abshir, W Labbett, C Smith, D Irish, ... Journal of Clinical Virology 66, 56-59, 2015 | 30 | 2015 |
| CD40 antibody as an adjuvant induces enhanced T cell responses J Carlring, TA Barr, AL McCormick, AW Heath Vaccine 22 (25-26), 3323-3328, 2004 | 30 | 2004 |
| Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1 AL McCormick, CM Parry, A Crombe, RL Goodall, RK Gupta, P Kaleebu, ... Antimicrobial Agents and Chemotherapy 55 (4), 1806-1809, 2011 | 28 | 2011 |
| Analysis of transmitted HIV‐1 drug resistance using 454 ultra‐deep‐sequencing and the DeepChek®‐HIV system A Garcia‐Diaz, A McCormick, C Booth, D Gonzalez, C Sayada, T Haque, ... Journal of the International AIDS Society 17, 19752, 2014 | 25 | 2014 |
| Gag-protease sequence evolution following protease inhibitor monotherapy treatment failure in HIV-1 viruses circulating in East Africa KA Sutherland, RL Goodall, A McCormick, A Kapaata, F Lyagoba, ... AIDS research and human retroviruses 31 (10), 1032-1037, 2015 | 23 | 2015 |
| Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1–4 AL McCormick, L Wang, A Garcia-Diaz, MJ Macartney, DP Webster, ... Antiviral therapy 20 (1), 81-85, 2015 | 23 | 2015 |
| Evidence for reduced drug susceptibility without emergence of major protease mutations following protease inhibitor monotherapy failure in the SARA trial KA Sutherland, CM Parry, A McCormick, A Kapaata, F Lyagoba, ... PloS one 10 (9), e0137834, 2015 | 20 | 2015 |
| A HML6 endogenous retrovirus on chromosome 3 is upregulated in amyotrophic lateral sclerosis motor cortex AR Jones, A Iacoangeli, BN Adey, H Bowles, A Shatunov, C Troakes, ... Scientific Reports 11 (1), 14283, 2021 | 19 | 2021 |
| The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic … D Ford, JM Robins, ML Petersen, DM Gibb, CF Gilks, P Mugyenyi, ... American journal of epidemiology 182 (7), 633-643, 2015 | 19 | 2015 |
| IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior … G Calisti, A Tavares, MJ Macartney, A McCormick, W Labbett, M Jacobs, ... Springerplus 4, 1-9, 2015 | 18 | 2015 |
| Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure MJ Macartney, D Irish, SH Bridge, A Garcia-Diaz, CL Booth, ... Antiviral research 105, 112-117, 2014 | 17 | 2014 |
